This is a synthetic peptide designed for use in combination with anti-CRADD Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
CRADD
Reactivité: Humain, Souris, Rat
Hôte: Synthetic
BP
Indications d'application
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Format
Lyophilized
Reconstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Stock
-20 °C
Stockage commentaire
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Antigène
CRADD
(CASP2 and RIPK1 Domain Containing Adaptor with Death Domain (CRADD))
Synonymes
cradd Peptide, MGC89035 Peptide, zgc:101717 Peptide, CRADD Peptide, DKFZp468A2219 Peptide, LOC100226369 Peptide, raidd Peptide, MGC78788 Peptide, MRT34 Peptide, RAIDD Peptide, CASP2 and RIPK1 domain containing adaptor with death domain Peptide, CASP2 and RIPK1 domain containing adaptor with death, gene 1 Peptide, CASP2 and RIPK1 domain containing adaptor with death, gene 2 S homeolog Peptide, CRADD Peptide, cradd.1 Peptide, cradd Peptide, cradd.2.S Peptide, Cradd Peptide
Sujet
The protein encoded by this gene is a death domain (CARD/DD)-containing protein and has been shown to induce cell apoptosis. Through its CARD domain, this protein interacts with, and thus recruits, caspase 2/ICH1 to the cell death signal transduction complex that includes tumor necrosis factor receptor 1 (TNFR1A), RIPK1/RIP kinase, and numbers of other CARD domain-containing proteins.